Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (216)

Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029method-of-use (U-3529)US 115649162.9y
Aug 13, 2029method-of-use (U-3529)US 115649162.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Jul 2, 2029method-of-use (U-2375)US 88467182.8y
Jul 2, 2029method-of-use (U-2375)US 88467182.8y
Jul 2, 2029method-of-use (U-1908)US 88467182.8y
Jul 2, 2029method-of-use (U-3427)US 88467182.8y
Jul 2, 2029method-of-use (U-1908)US 88467182.8y
Jun 4, 2029patentUS 10076513*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 11052075*PED2.7y
Jun 4, 2029patentUS 11052075*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Dec 4, 2028formulationUS 100765132.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028formulationUS 110520752.2y
Dec 4, 2028formulationUS 110520752.2y
Dec 4, 2028method-of-use (U-3984)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3984)US 120654322.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028method-of-use (U-2375)US 91505522.2y
Dec 4, 2028method-of-use (U-3427)US 91505522.2y
Dec 4, 2028method-of-use (U-1908)US 91505522.2y
Dec 4, 2028method-of-use (U-2375)US 91505522.2y
Dec 4, 2028method-of-use (U-1908)US 91505522.2y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Aug 5, 2027method-of-use (U-3424)US 8324242308d
Aug 5, 2027method-of-use (U-2374)US 8324242308d
Aug 5, 2027method-of-use (U-2374)US 8324242308d
Aug 5, 2027method-of-use (U-1911)US 8324242308d
Aug 5, 2027method-of-use (U-1911)US 8324242308d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Nov 8, 2026method-of-use (U-1973)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 797303838d
Nov 8, 2026method-of-use (U-3424)US 797303838d
Nov 8, 2026method-of-use (U-1973)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 874193338d
Nov 8, 2026method-of-use (U-1717)US 874193338d
Nov 8, 2026method-of-use (U-2374)US 874193338d
Nov 8, 2026method-of-use (U-3424)US 874193338d
Nov 8, 2026method-of-use (U-1909)US 874193338d
Nov 8, 2026compositionUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d

FDA exclusivities (12)

Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Dec 13, 2027M-14Method (3y)1.2y
Dec 13, 2027M-14Method (3y)1.2y
Dec 13, 2027M-14Method (3y)1.2y

News(0)

no news has mentioned this drug yet

brand

Orkambi

generic

(ivacaftor + lumacaftor)

MOA

12.1 Mechanism of Action The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. In vitro studies have demonstrated that both lumacaftor and ivacaftor act directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.

indication

Cystic Fibrosis

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

(ivacaftor + lumacaftor)

Marketedupdated 5mo ago

by $VERX Vertex, Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 6

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

indications

investigational

Cystic Fibrosis

all catalysts(20)

approval · 20

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

ORKAMBI (IVACAFTOR) — FDA approval

(ivacaftor + lumacaftor)

→

view all 20 catalysts →

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 8, 2026

38 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (216)

Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Jun 11, 2031patentUS 8993600*PED4.7y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8507534*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Mar 20, 2031patentUS 8716338*PED4.5y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Dec 11, 2030formulationUS 89936004.2y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030compositionUS 85075344.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Sep 20, 2030formulationUS 87163384.0y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Mar 29, 2030patentUS 9192606*PED3.5y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 10646481*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 11564916*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Feb 13, 2030patentUS 12458635*PED3.4y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Jan 2, 2030patentUS 8846718*PED3.3y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Sep 29, 2029formulationUS 91926063.0y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029method-of-use (U-3529)US 115649162.9y
Aug 13, 2029method-of-use (U-3529)US 115649162.9y
Aug 13, 2029method-of-use (U-3526)US 115649162.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Jul 2, 2029method-of-use (U-2375)US 88467182.8y
Jul 2, 2029method-of-use (U-2375)US 88467182.8y
Jul 2, 2029method-of-use (U-1908)US 88467182.8y
Jul 2, 2029method-of-use (U-3427)US 88467182.8y
Jul 2, 2029method-of-use (U-1908)US 88467182.8y
Jun 4, 2029patentUS 10076513*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 10597384*PED2.7y
Jun 4, 2029patentUS 11052075*PED2.7y
Jun 4, 2029patentUS 11052075*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 12065432*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 8653103*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Jun 4, 2029patentUS 9150552*PED2.7y
Dec 4, 2028formulationUS 100765132.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028compositionUS 105973842.2y
Dec 4, 2028formulationUS 110520752.2y
Dec 4, 2028formulationUS 110520752.2y
Dec 4, 2028method-of-use (U-3984)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3983)US 120654322.2y
Dec 4, 2028method-of-use (U-3984)US 120654322.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028formulationUS 86531032.2y
Dec 4, 2028method-of-use (U-2375)US 91505522.2y
Dec 4, 2028method-of-use (U-3427)US 91505522.2y
Dec 4, 2028method-of-use (U-1908)US 91505522.2y
Dec 4, 2028method-of-use (U-2375)US 91505522.2y
Dec 4, 2028method-of-use (U-1908)US 91505522.2y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Feb 5, 2028patentUS 8324242*PED1.3y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Nov 20, 2027patentUS 7495103*PED1.1y
Aug 5, 2027method-of-use (U-3424)US 8324242308d
Aug 5, 2027method-of-use (U-2374)US 8324242308d
Aug 5, 2027method-of-use (U-2374)US 8324242308d
Aug 5, 2027method-of-use (U-1911)US 8324242308d
Aug 5, 2027method-of-use (U-1911)US 8324242308d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8410274*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 8754224*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9670163*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
Jun 28, 2027patentUS 9931334*PED270d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 20, 2027compositionUS 7495103231d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 7973038*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 8741933*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
May 8, 2027patentUS 9216969*PED219d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026formulationUS 841027488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026compositionUS 875422488d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 967016388d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Dec 28, 2026formulationUS 993133488d
Nov 8, 2026method-of-use (U-1973)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 797303838d
Nov 8, 2026method-of-use (U-3424)US 797303838d
Nov 8, 2026method-of-use (U-1973)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 797303838d
Nov 8, 2026method-of-use (U-2374)US 874193338d
Nov 8, 2026method-of-use (U-1717)US 874193338d
Nov 8, 2026method-of-use (U-2374)US 874193338d
Nov 8, 2026method-of-use (U-3424)US 874193338d
Nov 8, 2026method-of-use (U-1909)US 874193338d
Nov 8, 2026compositionUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d
Nov 8, 2026formulationUS 921696938d

FDA exclusivities (12)

Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Mar 2, 2030PEDPediatric (6mo bonus)3.4y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Sep 2, 2029ODE-408Orphan Drug (7y)2.9y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Jun 13, 2028PEDPediatric (6mo bonus)1.7y
Dec 13, 2027M-14Method (3y)1.2y
Dec 13, 2027M-14Method (3y)1.2y
Dec 13, 2027M-14Method (3y)1.2y

News(0)

no news has mentioned this drug yet

brand

Orkambi

generic

(ivacaftor + lumacaftor)

MOA

indication

Cystic Fibrosis

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

(ivacaftor + lumacaftor)

🐶 often sniffed alongside

indications

all catalysts(20)

Patent cliff

patents (216)

FDA exclusivities (12)

News(0)

Report a data issue

comments(0)

(ivacaftor + lumacaftor)

🐶 often sniffed alongside

indications

all catalysts(20)

Patent cliff

patents (216)

FDA exclusivities (12)

News(0)

Report a data issue

comments(0)